**Abstract**

So-called D-neuron (trace amine (TA) neuron) is the ligand neuron of trace amine-associated receptor, type 1 (TAAR1). Reduced stimulation of TAAR1 on dopamine (DA) neurons in the midbrain ventral tegmental area (VTA) has been revealed to increase firing frequency of VTA DA neurons. A Patent Cooperation Treaty (PCT)-required histochemical methods (K. Ikemoto) were used to specify subgroups of D-neurons in the human brain (Ikemoto et al. 1997, 2016 (in press)), and to show D-neuron decrease in the nucleus accumbens (Acc) (D16, subgroup of D-neurons) of postmortem brains with schizophrenia (Ikemoto et al. 2003). The human D-neuron system is found to be far developed in the forebrain in comparison with that of other species, including non-human primates (Kitahama et al.2009). TA decrease caused by D-neuron reduction, and consequent TAAR1 stimulation decrease on terminals of midbrain VTA DA neurons leads to mesolimbic DA hyperactivity. Neural stem cell (NSC) dysfunction in the subventricular zone of lateral ventricle, which overlaps with the Acc, is supposed to be the cause of D-neuron reduction of schizophrenia. The rational is that the "D-cell hypothesis (TA hypothesis)" (Ikemoto 2012) is essential hypothesis to link DA hypothesis (Hokfelt et al, 1974) with NSC dysfunction hypothesis (Reif et al. 2006). From a therapeutic direction, (1) TAAR1 agonists or TAAR1 partial agonists (Revel et al. 2013), (2) DA D2 antagonists, and (3) neurotropic substances (e.g., brain-derived neurotrophic factor (BDNF), lithium, anticonvulsants, and antidepressants) have potential to normalize mesolimbic DA hyperactivity. Intranasal administration of these neuroactive substances and/or their precursors to reach the neuroleptic acting site, such as the subventricular-accumbal region, by using nanotechnology, is a possible prospective therapeutic strategy, which is devoid of gastrointestinal side effects.
